Busulphan is an alkylating drug now used almost exclusively to treat chronic myeloid leukaemia; it is also used to treat polycythaemia rubra vera (1,2,3)
For chronic myeloid leukaemia it is given as either a daily dose or as pulsed dose every 4-6 weeks.
In polycythaemia rubra vera, an oral dose of 4-6mg daily effectively reduces the haematocrit in combination with venesection. It is a second-line drug due to the severity of its side-effects.
Last reviewed 01/2018